160 related articles for article (PubMed ID: 22995972)
21. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
Kinon BJ; Volavka J; Stauffer V; Edwards SE; Liu-Seifert H; Chen L; Adams DH; Lindenmayer JP; McEvoy JP; Buckley PF; Lieberman JA; Meltzer HY; Wilson DR; Citrome L
J Clin Psychopharmacol; 2008 Aug; 28(4):392-400. PubMed ID: 18626265
[TBL] [Abstract][Full Text] [Related]
22. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Citrome L; Meng X; Hochfeld M
Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
[TBL] [Abstract][Full Text] [Related]
24. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
25. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.
te Beek ET; Moerland M; de Boer P; van Nueten L; de Kam ML; Burggraaf J; Cohen AF; van Gerven JM
J Psychopharmacol; 2012 Aug; 26(8):1119-27. PubMed ID: 21890591
[TBL] [Abstract][Full Text] [Related]
27. Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.
Gabriel D; Jakubovski E; Taylor JH; Artukoglu BB; Bloch MH
Psychiatry Res; 2017 Sep; 255():248-255. PubMed ID: 28595147
[TBL] [Abstract][Full Text] [Related]
28. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
[TBL] [Abstract][Full Text] [Related]
29. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
O'Gorman C; Kapur S; Kolluri S; Kane J
Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
[TBL] [Abstract][Full Text] [Related]
30. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
[TBL] [Abstract][Full Text] [Related]
31. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
33. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial.
Corrigan MH; Gallen CC; Bonura ML; Merchant KM;
Biol Psychiatry; 2004 Mar; 55(5):445-51. PubMed ID: 15023570
[TBL] [Abstract][Full Text] [Related]
35. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.
Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ
Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754
[TBL] [Abstract][Full Text] [Related]
36. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
[TBL] [Abstract][Full Text] [Related]
37. D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.
Schmidt ME; de Boer P; Andrews R; Neyens M; Rossenu S; William Falteos D; Mannaert E
Psychopharmacology (Berl); 2012 Dec; 224(4):549-57. PubMed ID: 22773165
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Kinon BJ; Zhang L; Millen BA; Osuntokun OO; Williams JE; Kollack-Walker S; Jackson K; Kryzhanovskaya L; Jarkova N;
J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
[TBL] [Abstract][Full Text] [Related]
39. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
40. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]